{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:39:18Z","timestamp":1793475558256,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","award":["CA209-7W9"],"award-info":[{"award-number":["CA209-7W9"]}],"id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Riki foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07518-2","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:17:14Z","timestamp":1761621434000},"page":"2217-2233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["[18F]FDG-PET\/CT\u2019s change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5667-1187","authenticated-orcid":false,"given":"Sabine E.","family":"Breukers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Crommelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Paul","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Navran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lot A.","family":"Devriese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-8024","authenticated-orcid":false,"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"7518_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-030-46227-7_6","volume":"1268","author":"U Leiter","year":"2020","unstructured":"Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: update 2019. Adv Exp Med Biol. 2020;1268:123\u201339. https:\/\/doi.org\/10.1007\/978-3-030-46227-7_6.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"7518_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069\u201380. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10830.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"7518_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.059.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"7518_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1187.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"7518_CR5","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.25411","volume":"127","author":"F Birch-Johansen","year":"2010","unstructured":"Birch-Johansen F, Jensen A, Mortensen L, Olesen AB, Kjaer SK. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978\u20132007: Rapid incidence increase among young Danish women. Int J Cancer. 2010;127(9):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.25411.","journal-title":"Int J Cancer"},{"issue":"6","key":"7518_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/j.1365-2133.2007.07892.x","volume":"156","author":"DH Brewster","year":"2007","unstructured":"Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992\u20132003. Br J Dermatol. 2007;156(6):1295\u2013300. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07892.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"7518_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.sder.2011.01.002","volume":"30","author":"MR Donaldson","year":"2011","unstructured":"Donaldson MR, Coldiron BM. No end in sight: the skin cancer epidemic continues. Semin Cutan Med Surg. 2011;30(1):3\u20135. https:\/\/doi.org\/10.1016\/j.sder.2011.01.002.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"7518_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/jid.2013.304","volume":"134","author":"N Eisemann","year":"2014","unstructured":"Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014;134(1):43\u201350. https:\/\/doi.org\/10.1038\/jid.2013.304.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"7518_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/ddg.12690","volume":"13","author":"C Rudolph","year":"2015","unstructured":"Rudolph C, Schnoor M, Eisemann N, Katalinic A. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. J Dtsch Dermatol Ges. 2015;13(8):788\u201397. https:\/\/doi.org\/10.1111\/ddg.12690.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl 8","key":"7518_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdv.15967","volume":"33","author":"A Stang","year":"2019","unstructured":"Stang A, Khil L, Kajuter H, Pandeya N, Schmults CD, Ruiz ES, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol. 2019;33(Suppl 8):6\u201310. https:\/\/doi.org\/10.1111\/jdv.15967.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"7518_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1708701","volume":"379","author":"KS Nehal","year":"2018","unstructured":"Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med. 2018;379(4):363\u201374. https:\/\/doi.org\/10.1056\/NEJMra1708701.","journal-title":"N Engl J Med"},{"issue":"2","key":"7518_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jaad.2017.08.058","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.058.","journal-title":"J Am Acad Dermatol"},{"key":"7518_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081871","author":"G Ferini","year":"2022","unstructured":"Ferini G, Palmisciano P, Forte S, Viola A, Martorana E, Parisi S, et al. Advanced or metastatic cutaneous squamous cell carcinoma: the current and future role of radiation therapy in the era of immunotherapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14081871.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"7518_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaad.2021.09.067","volume":"86","author":"S Tokez","year":"2022","unstructured":"Tokez S, Wakkee M, Kan W, Venables ZC, Mooyaart AL, Louwman M, et al. Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study. J Am Acad Dermatol. 2022;86(2):331\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.067.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"7518_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1805131.","journal-title":"N Engl J Med"},{"issue":"17","key":"7518_CR16","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2209813.","journal-title":"N Engl J Med"},{"issue":"16","key":"7518_CR17","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0585.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7518_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"6","key":"7518_CR19","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s00259-021-05610-x","volume":"49","author":"JL Vos","year":"2022","unstructured":"Vos JL, Zuur CL, Smit LA, de Boer JP, Al-Mamgani A, van den Brekel MWM, et al. [(18)F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(6):2010\u201322. https:\/\/doi.org\/10.1007\/s00259-021-05610-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7518_CR20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1209\u201319. https:\/\/doi.org\/10.1007\/s00259-020-04711-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7518_CR21","doi-asserted-by":"publisher","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773\u201382. https:\/\/doi.org\/10.1016\/s0959-8049(99)00229-4.","DOI":"10.1016\/s0959-8049(99)00229-4"},{"issue":"8","key":"7518_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy226.","journal-title":"Ann Oncol"},{"issue":"3","key":"7518_CR23","doi-asserted-by":"publisher","first-page":"e0249304","DOI":"10.1371\/journal.pone.0249304","volume":"16","author":"M Nogami","year":"2021","unstructured":"Nogami M, Zeng F, Inukai J, Watanabe Y, Nishio M, Kanda T, et al. Physiological skin FDG uptake: a quantitative and regional distribution assessment using PET\/MRI. PLoS One. 2021;16(3):e0249304. https:\/\/doi.org\/10.1371\/journal.pone.0249304.","journal-title":"PLoS One"},{"issue":"4","key":"7518_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"157","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 2022;157(4):335\u201342. https:\/\/doi.org\/10.1001\/jamasurg.2021.7554.","journal-title":"JAMA Surg"},{"issue":"8","key":"7518_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-22-0468","volume":"28","author":"R Ferrarotto","year":"2022","unstructured":"Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022;28(8):1735. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0468.","journal-title":"Clin Cancer Res"},{"key":"7518_CR26","doi-asserted-by":"publisher","unstructured":"Joo Hyun O. MAL, Richard L. Wahl. Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","DOI":"10.1148\/radiol.2016142043"},{"issue":"Suppl 1","key":"7518_CR27","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50 Suppl 1","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1 (Suppl 1):122S-S150. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"issue":"1","key":"7518_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","volume":"9","author":"L Goldfarb","year":"2019","unstructured":"Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8. https:\/\/doi.org\/10.1186\/s13550-019-0473-1.","journal-title":"EJNMMI Res"},{"issue":"3","key":"7518_CR29","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"issue":"11","key":"7518_CR30","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361. https:\/\/doi.org\/10.1038\/s41591-018-0198-0.","journal-title":"Nat Med"},{"issue":"21","key":"7518_CR31","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976\u201386. https:\/\/doi.org\/10.1056\/NEJMoa1716078.","journal-title":"N Engl J Med"},{"issue":"10","key":"7518_CR32","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020;6(10):1563\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2955.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7518_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","volume":"45","author":"K Kaira","year":"2018","unstructured":"Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, et al. Metabolic activity by (18)F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018;45(1):56\u201366. https:\/\/doi.org\/10.1007\/s00259-017-3806-1.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07518-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:49Z","timestamp":1771479529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07518-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7518"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07518-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles approval of the Declaration of Helsinki. Study protocol approval was granted by the Medical Ethics Committee of the Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek Hospital (METC-AVL) under file number NL72486 031 20 dated on 26th of June 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      d-e,\n                      \n                      d-e, and Supplementary Fig.\u00a0\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Charlotte L. Zuur reports receiving institutional research financial support from BMS to fund the present trial. Lot A. Devriese reports payments to my institution: speakers fee from Merck. John B.A.G. Haanen reports, all outside the submitted work: institutional honoraria for advisory roles for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche\/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm; stock option ownership of Neogene Therapeutics, Sastra Cell Therapy; Institutional research funding from Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis Sastra Cell Therapy. The remaining authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}